# Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

> **NCT00006113** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 25 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** recombinant CD40-ligand
- **BIOLOGICAL:** recombinant interferon gamma
- **BIOLOGICAL:** recombinant interleukin-4
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** therapeutic autologous dendritic cells
- **BIOLOGICAL:** therapeutic tumor infiltrating lymphocytes
- **BIOLOGICAL:** tyrosinase peptide
- **RADIATION:** Candida albicans skin test reagent

## Key facts

- **NCT ID:** NCT00006113
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-06
- **Primary completion:** 2003-05
- **Final completion:** 2006-04
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2014-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006113, "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00006113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*